Mesolimbic involvement with behavioural effects indicating antipsychotic activity.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002375:Catalepsy / Q000139:chemically induced; D003913:Dextroamphetamine / Q000494:pharmacology; D003987:Dibenzothiazepines / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004567:Electrodes, Implanted; D005476:Fluphenazine / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008032:Limbic System / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D013141:Spiro Compounds / Q000494:pharmacology; D013238:Stereotaxic Techniques; D013239:Stereotyped Behavior / Q000187:drug effects; D014149:Tranquilizing Agents / Q000494:pharmacology*
D003987:Dibenzothiazepines; D010880:Piperidines; D013141:Spiro Compounds; D014149:Tranquilizing Agents; D009020:Morphine; D006220:Haloperidol; D008787:Metoclopramide; D005476:Fluphenazine; D003913:Dextroamphetamine